Zelenectide pevedotin

Peptide

Also known as BT8009

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Development in Non-Small Cell Lung Cancer stopped (2026-03) as a strategic decision by the sponsor. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (4)
Urothelial Carcinoma
Other / comorbidity
NCT07681674 · BicycleTx Limited
2026-08-01 – 2030-05-30 · Advanced Solid Tumors
What this study did
NCT06840483 · BicycleTx Limited
2025-03-03 – 2028-12-30 · Breast Cancer
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT04561362 · BicycleTx Limited
2020-07-17 – 2027-01 · Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms, Ovarian Neoplasm, Advanced Solid Tumor
What this study did

Competitive landscape

5 other tracked programmes target this mechanism, 3 of them ahead of this one.

This drug's own stage for Urothelial Carcinoma: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Zelenectide Pevedotin: this drugPhase 2PeptideNectin-4not yet gradedNo reviewed efficacy summary in this indication
AvelumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Enfortumab Vedotin
Approved(overall)
Antibody–drug conjugateNectin-4
Partial signal(overall)
No reviewed efficacy summary in this indication
Erdafitinib (Balversa)ApprovedSmall moleculeFGFR1-4Weak signalFeatured results are dose-finding and non-efficacy only in this race
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT03036098: Sub-study (cisplatin-eligible), nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin: PFS HR 0.72 (95% CI 0.59 to 0.88), p=0.0018; OS median 21.7 vs 18.9 months, HR 0.78 (95% CI 0.63 to 0.96), p=0.0171. Primary study, nivolumab + ipilimumab vs chemotherapy: OS in PD-L1 >=1% 16.3 vs 14.4 months, primary not met per BMS; OS in cisplatin-ineligible 19.1 vs 13.2 months, HR 0.79 (95% CI 0.64 to 0.97), posted p=0.0032 (CT.gov posted results).
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02853305: Pembrolizumab plus chemotherapy vs chemotherapy: PFS median 8.3 vs 7.1 months (HR 0.78, 95% CI 0.65 to 0.93; p=0.0033 against a boundary of 0.0019); OS median 17.0 vs 14.3 months (HR 0.86, 95% CI 0.72 to 1.02; p=0.0407 against a boundary of 0.0142). Pembrolizumab monotherapy OS comparisons were exploratory after the hierarchy stopped (KEYNOTE-361, Lancet Oncol 2021). missed
Datopotamab DeruxtecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
DurvalumabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
IpilimumabPhase 3Monoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
Notiretatug RezetecanPhase 3Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Sacituzumab GovitecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Sutantatug EnvedotinPhase 3Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
TremelimumabPhase 3Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
BudigalimabPhase 2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication
AKY-1189Phase 1RadiopharmaceuticalNectin-4 (PVRL4)not yet gradedNo reviewed efficacy summary in this indication
IPH4502
Phase 1(overall)
Antibody–drug conjugateNectin-4
not yet graded(overall)
No reviewed efficacy summary in this indication
LY4052031Phase 1Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Zelenectide pevedotin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
January 2027 (1)
Phase 1/2Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive …Active not recruiting
Est. primary completion 2027-01 · NCT04561362 · CT.gov ↗
What to watch
2028 (3)
March 2028 (1)
Phase 2Urothelial CarcinomaActive not recruiting
Est. primary completion 2028-03 · NCT06225596 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Breast CancerActive not recruiting
Est. primary completion 2028-06-30 · NCT06840483 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Non-Small Cell Lung CancerActive not recruitingDiscontinued in this indication
Est. primary completion 2028-08-31 · NCT06933329 · CT.gov ↗
What to watch
2030 (1)
May 2030 (1)
Phase 2Advanced Solid TumorsNot yet recruiting
Est. primary completion 2030-05-30 · NCT07681674 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 January 2025Topline resultUpdated Duravelo-1 topline data for zelenectide pevedotin plus pembrolizumab